Time-Dependent Efficacy of Immune Checkpoint Inhibitors in Metastatic Cancers

Strategic Insights -

Research conducted by Public Assistance - Paris Hospitals (AP-HP) has shed light on the potential benefits of timing immune checkpoint inhibitors (ICIs) in the treatment of metastatic cancer. The study, published in the Journal of Clinical Oncology, suggests that administering ICIs in the morning or early part of the day may improve patient outcomes. This research is significant, as ICIs have become the standard of care for numerous advanced malignancies. The study's findings have sparked interest in establishing ICI timing recommendations for optimizing treatment efficacy in patients with different cancer types.

Key Takeaways:

  • The study included 7 published studies with 1019 patients who had stage IV non-small cell lung cancer, urothelial cancer, renal cell carcinoma, or melanoma, and were treated with ICIs.
  • The time cut-offs selected to stratify patterns of ICI infusion were 16:00 or 16:30 in 5 studies and 13:00 in 2 studies, based on differences in adaptive immune response reported in previous vaccination studies.
  • The pooled analysis of overall survival results showed a statistically significant benefit in favor of patients receiving infusions in the morning or early part of the day, with a hazard ratio of 0.49 (95% CI: 0.36-0.69).
  • The study's findings are consistent with established circadian mechanisms that control immune cell functions and trafficking over a 24-h period.
  • Prospective randomized trials are warranted to establish ICI timing recommendations for optimizing treatment efficacy in patients with different cancer types and at minimal cost.

Statistics:

  • 1019 patients were included in the study, with 43% having a performance status of 0, 39% having a performance status of 1, and a male-to-female ratio of 11:5.
  • The study included patients with non-small cell lung cancer (43%), urothelial cancer (21%), renal cell carcinoma (17%), and melanoma (19%).
  • The pooled analysis of overall survival results showed a hazard ratio of 0.49 (95% CI: 0.36-0.69) in favor of patients receiving infusions in the morning or early part of the day.

Sources:

  • Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis. Journal of Clinical Oncology, 2023, 41(16_suppl), 2562.
  • American Society of Clinical Oncology (ASCO).
  • Public Assistance - Paris Hospitals (AP-HP), Paris, France.